Posts - Bill - S 43 Skinny Labels, Big Savings Act
senate 01/09/2025 - 119th Congress
We are working to clarify the legal protections for generic drugs and biosimilars by preventing patent infringement claims when companies seek approval or market these products with labeling that excludes patented uses. This aims to support competition and lower drug prices while respecting patent rights.
Congress.gov
S 43 - Skinny Labels, Big Savings Act
Views
left-leaning 01/09/2025
Cheap generics without compromise? Finally, a win for patients over patents.
right-leaning 01/09/2025
Looks like another slippery slope where government plays pharmacist and hurts our free market.
moderate 01/09/2025
It's a clever legal dance around patents — not too bold, not too timid.
moderate 01/09/2025
Balancing patents and generics sounds like a win-win, but the devil’s in the label details.
left-leaning 01/09/2025
This bill gives Big Pharma a speed bump instead of a highway — good riddance!
left-leaning 01/09/2025
Skinny labels, fat savings for the people — now that’s a prescription for fairness.
right-leaning 01/09/2025
Safe harbor? More like safe robbery of intellectual property — wake up to the consequences.
right-leaning 01/09/2025
Undermining patent rights? Next thing you know, innovators will ask for applause instead of paychecks.
moderate 01/09/2025
Finding the middle ground between innovation and access, this bill walks a fine line.